EPS for RedHill Biopharma Ltd – ADR (RDHL) Expected At $-0.67, Vanguard Group Lifted Gerdau S A (GGB) Position

June 22, 2017 - By Linda Rogers

Vanguard Group Inc increased Gerdau S A (GGB) stake by 7.72% reported in 2016Q4 SEC filing. Vanguard Group Inc acquired 686,849 shares as Gerdau S A (GGB)’s stock declined 32.55%. The Vanguard Group Inc holds 9.59M shares with $30.11M value, up from 8.90 million last quarter. Gerdau S A now has $4.65B valuation. The stock increased 1.51% or $0.04 on June 21, reaching $2.69. About shares traded. Gerdau SA (ADR) (NYSE:GGB) has risen 83.44% since June 22, 2016 and is uptrending. It has outperformed by 66.74% the S&P500.

Analysts expect RedHill Biopharma Ltd – ADR (NASDAQ:RDHL) to report $-0.67 EPS on July, 25.They anticipate $0.07 EPS change or 11.67% from last quarter’s $-0.6 EPS. After having $-0.50 EPS previously, RedHill Biopharma Ltd – ADR’s analysts see 34.00% EPS growth. About 2,020 shares traded. RedHill Biopharma Ltd – ADR (NASDAQ:RDHL) has declined 9.09% since June 22, 2016 and is downtrending. It has underperformed by 25.79% the S&P500.

RedHill Biopharma Ltd. is a biopharmaceutical company. The company has market cap of $160.48 million. The Firm is focused on the development and commercialization of clinical-stage, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It currently has negative earnings. The Company’s seven clinical-stage therapeutic candidates include RHB-105, RHB-104, BEKINDA, RHB-106, YELIVA, MESUPRON and RIZAPORT and related research and development programs.

Among 6 analysts covering RedHill Biopharma (NASDAQ:RDHL), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. RedHill Biopharma had 8 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was initiated by Northland Capital with “Buy” on Tuesday, September 29. The firm earned “Hold” rating on Tuesday, August 25 by TheStreet. The firm has “Outperform” rating by FBR Capital given on Friday, February 24. The rating was maintained by TH Capital with “Buy” on Wednesday, July 29. Nomura initiated the stock with “Buy” rating in Tuesday, September 29 report. The firm earned “Sell” rating on Saturday, August 22 by Zacks.

Among 5 analysts covering Gerdau (NYSE:GGB), 3 have Buy rating, 2 Sell and 0 Hold. Therefore 60% are positive. Gerdau had 6 analyst reports since August 10, 2015 according to SRatingsIntel. On Monday, August 10 the stock rating was initiated by Goldman Sachs with “Buy”. Credit Suisse upgraded the stock to “Outperform” rating in Thursday, August 4 report. As per Monday, February 22, the company rating was downgraded by Bank of America. Scotia Capital downgraded Gerdau SA (ADR) (NYSE:GGB) on Tuesday, October 25 to “Underperform” rating. The firm earned “Overweight” rating on Thursday, August 18 by Morgan Stanley.